{
    "clinical_study": {
        "@rank": "164691", 
        "acronym": "PEPNATB", 
        "arm_group": {
            "arm_group_label": "Peptide Natriur\u00e9tique de type B", 
            "arm_group_type": "Experimental", 
            "description": "Peptide Natriur\u00e9tique de type B"
        }, 
        "brief_summary": {
            "textblock": "The cardiotoxicity of anthracyclines chemotherapy remains a major problem, despite clinical\n      and echocardiographic monitoring. In the case of treatment for breast cancer, surgery\n      requiring general anesthesia may follow chemotherapy. Although a possible interaction\n      between general anesthetics and anthracyclines on systolic function is only rarely\n      mentioned, some cases of heart failure and / or conduction disturbances peranesth\u00e9sique were\n      observed in patients treated or previously treated with anthracyclines. The determination of\n      concentration of BNP is a diagnostic tool used in the detection of heart failure and acute\n      coronary syndromes. The question of a possible synergism between cardiotoxic anthracyclines\n      and anesthetic agents arises. Given its minimally invasive nature and its diagnostic value,\n      the BNP assay might thus allow to highlight a possible subclinical deficiency. To our\n      knowledge, there is very little data regarding a possible synergism between cardiotoxic\n      anthracyclines and anesthetic agents."
        }, 
        "brief_title": "Evolution Natriuretic Peptide Concentrations of B-type (BNP) During General Anesthesia Under Propofol and Sevoflurane Association in Patients Previously Sensitized to Anthracyclines", 
        "completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "The cardiotoxicity of anthracyclines chemotherapy remains a major problem, despite clinical\n      and echocardiographic monitoring. In the case of treatment for breast cancer, surgery\n      requiring general anesthesia may follow chemotherapy. Although a possible interaction\n      between general anesthetics and anthracyclines on systolic function is only rarely\n      mentioned, some cases of heart failure and / or conduction disturbances peranesth\u00e9sique were\n      observed in patients treated or previously treated with anthracyclines. The determination of\n      concentration of BNP is a diagnostic tool used in the detection of heart failure and acute\n      coronary syndromes. In fact, it is one of the most sensitive markers of impaired myocardial\n      function, and an increase in interest rates may precede any other biological changes. In a\n      patient who received anthracycline, although it remains asymptomatic elevation of NT-proBNP\n      concentration may persist for some months after exposure, and that, whatever the doses\n      received. The question of a possible synergism between cardiotoxic anthracyclines and\n      anesthetic agents arises. Given its minimally invasive nature and its diagnostic value, the\n      BNP assay might thus allow to highlight a possible subclinical deficiency. To our knowledge,\n      there is very little data regarding a possible synergism between cardiotoxic anthracyclines\n      and anesthetic agents."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Women over 18 years with effective contraceptive method (if applicable)\n\n          -  NT-proBNP <125 pg / ml\n\n          -  ASA 1 or 2,\n\n          -  Breast cancer histologically proven\n\n          -  Mastectomy or lumpectomy\n\n          -  Neoadjuvant chemotherapy with anthracyclines in 6 months or received no chemotherapy\n             with anthracyclines,\n\n          -  Patients who received the briefing and signed the informed consent\n\n          -  Patients affiliated to a social security system.\n\n        Exclusion Criteria:\n\n          -  Patients for whom the maintenance of general anesthesia does not use halogenated.\n\n          -  Renal impairment: Creatinine clearance <60 ml / min,\n\n          -  Patients who for reasons psychological, social, family or geographical could not be\n             treated or monitored regularly according to the criteria of the study, patients\n             deprived of liberty or under guardianship.\n\n          -  Presence of a cardiopathy\n\n          -  Pregnant Women"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "56", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 6, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01754597", 
            "org_study_id": "IB2009-39"
        }, 
        "intervention": {
            "arm_group_label": "Peptide Natriur\u00e9tique de type B", 
            "description": "Peptide Natriur\u00e9tique de type B", 
            "intervention_name": "Peptide Natriur\u00e9tique de type B", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Anesthetics", 
                "Sevoflurane"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Patients with breast cancer requiring surgical management with general anesthesia", 
        "lastchanged_date": "July 25, 2013", 
        "link": {
            "description": "Site internet du promoteur, l'Institut Bergoni\u00e9", 
            "url": "http://www.bergonie.org/fr/essais-clinique.html"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Bordeaux", 
                    "country": "France", 
                    "state": "Aquitaine", 
                    "zip": "33000"
                }, 
                "name": "Institut Bergoni\u00e9"
            }
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "1", 
        "official_title": "Evolution Natriuretic Peptide Concentrations of B-type (BNP) During General Anesthesia Under Propofol and Sevoflurane Association in Patients Previously Sensitized to Anthracyclines. Pilot Study in Patients Operated on for Breast Cancer. Monocentric Study Feasibility.", 
        "overall_official": {
            "affiliation": "Institut Bergoni\u00e9", 
            "last_name": "GEKIERE Jean Pierre, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "France: National Security Agency of Medicines and Health Products", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Describe the evolution of the concentrations of NT-proBNP, through repeated dosing during general anesthesia in patients operated on for breast cancer and anthracycline-sensitized or not", 
            "measure": "Describe the evolution of the concentrations of NT-proBNP, through repeated dosing during general anesthesia in patients operated on for breast cancer and anthracycline-sensitized or not", 
            "safety_issue": "No", 
            "time_frame": "3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01754597"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Depending on the sensitivity to anthracyclines, study the proportion of patients with subclinical heart failure in the general anesthesia during surgery for breast cancer\nIn patients treated with anthracyclines, highlight the factors associated (cumulative dose of anthracycline front, left breast radiotherapy) to subclinical heart failure\nIn patients treated with anthracyclines, assess describe the relationship between the dose of anthracycline received preoperative and percentage of maximum variation of the concentration of NT-proBNP in the first 24 hours after surgery", 
            "measure": "Depending on the sensitivity to anthracyclines, study the proportion of patients with subclinical heart failure in the general anesthesia during surgery for breast cancer", 
            "safety_issue": "No", 
            "time_frame": "3 years"
        }, 
        "source": "Institut Bergoni\u00e9", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Institut Bergoni\u00e9", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2009", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}